Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06279299

Lateral Pelvic Lymph Node Dissection for Rectal Neuroendocrine Neoplasms Undergoing Laparoscopic Total Mesenteric Excision

The purpose of this study is to investigate the metastatic status of lateral pelvic lymph nodes in rectal neuroendocrine neoplasms (rNENs) undergoing laparoscopic total mesenteric excision (TME). The hypothesis is that the rate of lateral lymph node metastasis is underestimated in rNENs undergoing TME, necessitating concurrent lateral Pelvic lymph node dissection.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

This study is a prospective single-arm clinical study. 30 patients with rNENs undergoing TME are planned to be included in the study. The purpose of this study is to investigate the metastatic status of lateral pelvic lymph nodes in (rNENs) undergoing laparoscopic TME. The primary endpoint is the rate of lateral pelvic lymph nodes metastasis. The primary hypothesis was the rate of lateral lymph node metastasis is underestimated in rNENs undergoing TME, necessitating concurrent lateral Pelvic lymph node dissection.

This study seeks to report for the first time the true status of lateral pelvic lymph node metastasis in these patients. In addition, the proportion of patients with radical resection (R0), surgical complication profile, and quality of life (QoL) are also secondary endpoints.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Biopsy proven rectal neuroendocrine neoplasm (neuroendocrine tumor and carcinoma);
  • Meets any one of the following conditions:
  • Preoperative imaging examinations reveal that the maximum diameter of the tumor is greater than 2cm.
  • Preoperative imaging examinations reveal that the maximum diameter of the tumor is between 1-2cm and the clinical staging is T2 or higher.
  • Preoperative imaging examinations reveal that the maximum diameter of the tumor is between 1-2cm and is categorized as Grade 3 differentiation.
  • Recurrence after local excision under endoscopy.
  • Eastern Cooperative Oncology Group(ECOG) performance score ≤ 1;
  • Written informed consent;

Exclusion criteria

  • Complete intestinal obstruction;
  • Hepatitis activity and peripheral neuropathy (such as peripheral neuritis, pseudo meningitis, motor neuritis, and sensory impairment);
  • Significant organ dysfunction or other significant diseases, including clinically relevant coronary artery disease, cardiovascular disease, or myocardial infarction within the 12 months before enrollment; severe neurological or psychiatric history; severe infection; active disseminated intravascular coagulation;
  • Pregnancy or breastfeeding;
  • Alcohol abuse or drug addiction;
  • Concurrent uncontrolled medical condition;

Treatment and study plan

lateral pelvic lymph node dissection

Procedure

Following the total mesorectal excision principle, the rectum and mesentery are removed, with careful protection of the pelvic autonomic nerves. After completing laparoscopic rectal resection, lateral lymph node dissection is performed. The lateral dissection follows these steps: ① Open the peritoneum at the bifurcation of the iliac vessels, dissect along the retroperitoneum adjacent to the ureter-bladder fascia, expose the lateral pelvic area, and carefully protect the ureter and hypogastric nerves. Open the peritoneum along the edge of the external iliac vessels close to the inguinal ligament, clear the lymphatic fatty tissue alongside the external iliac vessels along the edge of the iliopsoas and internal oblique muscles; ② After identifying the hypogastric nerve, dissect along the bladder-bladder fascia, separate the bladder and the fat tissue around the lateral pelvic space, completely remove the lymphatic tissue around the internal iliac vessels and hypogastric nerves.

Primary outcomes

  1. The rate of lateral pelvic lymph node metastasis

    Time frame: up to 14 days

    The rate of lateral pelvic lymph node metastasis = lateral pelvic lymph node metastasis cases/all cases.

Secondary outcomes

  1. The rate of lymph node metastasis

    Time frame: up to 14 days

    The rate of lymph node metastasis = lymph node metastasis cases/all cases.

  2. Disease-free survival rate

    Time frame: three years

    Disease-free survival (DFS) is a number that tells the chances of staying free of a disease or cancer after a particular treatment. It is the percentage of individuals in the treatment group who are likely to be free of the signs and symptoms of a disease after a specified duration of time.

  3. Overall survival rate

    Time frame: three years

    The time from diagnosis to (for any reason) death.

  4. Locoregional recurrence free survival rate

    Time frame: three year

    Locoregional Recurrence Free Survival is defined as the time interval between the day of diagnosis in the study and the date of local relapse/recurrence or regional relapse/recurrence whichever occurs first.

  5. Radical resection (R0)

    Time frame: up to 14 years

    R0 resection rate is R0 resection probability of radical surgery in patients with locally advanced rectal cancer after neoadjuvant therapy

Study contacts

Contact information is provided by the study sponsor or research team.

Yueyang Zhang, M.D.

CONTACT

[email protected]

+8613552910035

Zheng Xu, M.D.

CONTACT

[email protected]

+8613141127297

Sponsors and collaborators

Lead sponsor

National Cancer Center, China

Other

Registry information

Important dates

Study start
2022
Primary completion
2028
Study completion
2028
First posted
Feb 28, 2024
Registry last updated
Feb 28, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.